CANC News | Roxom Stocks

1 BTC

- USD

Loading market data...

AUM

N/A

Volume

7.08K

Yield

0.05%

Chart Earnings News About Dividends Insider Filings

Healthcare ETFs for the Weight-Loss Drug Boom & BeyondWe discuss attractive investment opportunities within the healthcare industry.Zacks Investment Research · Apr 8, 2024

Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will it be a Boost For Pharma Stocks Too?In September, Biden unveiled a $240 million investment to combat cancer, augmenting the administration’s “Cancer Moonshot”, an initiative with an array of new health resources. The funding, allocated through the recently established Advanced Research Projects Agency for Health (ARPA-H) will support researchers engaged in projects spanning cancer prevention, detection, treatment, and survival. These initiatives include endeavors to enhance early cancer detection, improve the visualization of cancer cells during surgery, and develop devices capable of delivering treatments directly to cancer cells for more effective tumor treatment. Reflecting on the broad impact of the fight ...Full story available on Benzinga.comBenzinga · Dec 5, 2023

EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The FadsTema ETFs is redefining thematic investing by prioritizing long-term structural trends and precision in security selection, diverging from the industry norm of chasing short-lived market fads. This innovative approach was the focal point of a virtual session hosted by Benzinga’s “ETFs Unlocked,” moderated by Benzinga’s Aaron Bry. Yuri Khodjamirian, CFA, chief investment officer at Tema ETFs, revealed the company’s innovative approach to thematic investing, addressing common pitfalls in passive funds and showcasing their latest offerings in various market themes including product reshoring in the U.S., luxury goods, and cardio-metabolic diseases. Tema ETFs: Pioneering Precision in Thematic Investing Established two years ago with six funds in the market, Tema ETFs has carved a niche in the ETF landscape. “We want to be in structural long term growing areas of the market where we really believe there’s an investment merit over multiple decades,” Khodjamirian said. Emphasizing long-term structural themes, they use expert analysis for security selection, ensuring portfolios are precisely focused on high-quality ...Full story available on Benzinga.comBenzinga · Dec 1, 2023

Active ETFs Appear Booming In 2023 — Tema ETFs Are Taking Them Into A New DirectionThe rapid emergence of the ETF industry, marked by its AuM growth from $1 trillion to $10 trillion this past decade, was driven by passive indexed funds which thrived in a low-rates, low-volatility environment. These funds offered low cost, low differentiation solutions to retail investors. As institutional investors overtake retail investors in ETF adoption, the landscape of the industry is set for a paradigm shift. The limitations of indexes are becoming increasingly apparent in a macro environment characterized by higher rates and higher volatility, which could stick around in the decade to come. The fundamental analysis and risk management that had been left behind by index funds are suddenly relevant again. Investors are consequently exploring alternative vehicles for their public equity exposures, namely active ETFs. Tema is one of the first independent thematic active ETF asset managers, but unlike competitors, is concentrating on underpenetrated, generational thematic trends that were previously inaccessible to investors. These themes include reshoring, oncology, luxury goods, cardiology and metabolics (Obesity and diabetes), and monopolies and oligopolies. The vulnerabilities of passive ETFs are becoming more apparent in the current environment Limited by the rigid nature of their underlying indices, passive funds lack the ability to dynamically respond and adapt to increasingly rapid and sharp changes in environment. These limitations undermine risk management efficacy and can ultimately compound risks for their investors. An example is the special premature rebalance the Nasdaq 100 index had to undergo this past summer. The disparity in performance within the index had over-concentrated its value, with the “Magnificent seven”, Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN), Apple (NASDAQ: APPL), Meta (NASDAQ: META), Microsoft (NASDAQ: MSFT), Nvidia (NASDAQ: NVDA), and Tesla (NASDAQ: TSLA), reaching 55% of the index’s total value. The “special rebalance” not only revealed the concentration risks tied to indexation, but also exposed the arbitrage and front-running risks that passive vehicles can be exposed to, at the detriment of investors. Active ETFs have enjoyed record growth in 2023 While passive ETF growth has started to slow, active ETF growth is now accelerating fast, with ...Full story available on Benzinga.comBenzinga · Nov 28, 2023

Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic. The Tema Cardiovascular and Metabolics ETF (NASDAQ:HRST) launches on the NASDAQ exchange on Tuesday and will look to cash in on the massive popularity of a new breed of drugs called semaglutides, which include Novo Norkdisk‘s (NYSE:NVO) Ozempic and Wegovy and Eli Lilly‘s (NYSE:LLY) Mounjaro. “Cardiovascular and metabolic diseases are closely intertwined, combining a larger, well-established area of healthcare with a burgeoning new biopharma sector: obesity,” said Maurits Pot, co-founder and CEO of TEMA. “This area has recently announced and launched several breakthrough therapies underscoring the pace of innovation that we believe will transform patient lives and outcomes.” Also Read: ...Full story available on Benzinga.comBenzinga · Nov 21, 2023

How BlackRock’s Rick Rieder is steering his active fixed-income ETF as bond funds struggleFor this week’s ETF Wrap I caught up with Rick Rieder, BlackRock’s chief investment officer of global fixed income, on how he’s approaching debt markets with his actively managed ETF in a bruising August for many bond funds.MarketWatch · Aug 17, 2023

CANCTema Oncology ETF

CANC

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any CANC yet.

Related Tickers

Earnings

Dividends

Last · Dec 10

Amount$0.0196

Yield0.05%

Annual$0.0196

Volume

7.08K